Cart
sales@molnova.com
Pristimerin
CAS No. 1258-84-0
Pristimerin( Pristimerin | Celastrol-methylether | UNII-28ZK7PR57S )
Catalog No. M17913 CAS No. 1258-84-0
Pristimerin has anticancer activity, treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 73 | In Stock |
|
| 5MG | 70 | In Stock |
|
| 10MG | 123 | In Stock |
|
| 25MG | 278 | In Stock |
|
| 50MG | 488 | In Stock |
|
| 100MG | 696 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1414 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePristimerin
-
NoteResearch use only, not for human use.
-
Brief DescriptionPristimerin has anticancer activity, treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells.
-
DescriptionPristimerin has anticancer activity , treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells. Pristimerin down-regulates the expression of pro-inflammatory mediators through blocking of NF-κB activation by inhibiting interconnected ROS/IKK/NF-κB signaling pathways, can effectively inhibit both arthritic inflammation and cartilage and bone damage in the joints.
-
In VitroPristimerin inhibits the activity of purified MGL with an IC50 of 93±8 nM and that of non-purified MGL (cell lysates of MGL-transfected HeLa cells) with an IC50 of 398±68 nM. Pristimerin inhibits MGL through a mechanism that is rapid, reversible and non-competitive. The binding of pristimerin to MGL might be strengthened by formation of a polar interaction with a regulatory cysteine, possibly Cys208. Pristimerin inhibits HFLS-RA and HUVEC cell viability in a dose- and time-dependent manner. Pristimerin decreases VEGF-induced autophosphorylation of VEGFR2 and attenuates the activation of the VEGF-induced VEGFR2-mediated signaling pathway .
-
In VivoPristimerin inhibits inflammation and tumor angiogenesis. Pristimerin significantly reduces vessel density in synovial membrane tissues of inflamed joints and reduces the expression of pro-angiogenic factors in sera, including TNF-α, Ang-1, and MMP-9.
-
SynonymsPristimerin | Celastrol-methylether | UNII-28ZK7PR57S
-
PathwayChromatin/Epigenetic
-
TargetSirtuin
-
RecptorNF-κB
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1258-84-0
-
Formula Weight464.64
-
Molecular FormulaC30H40O4
-
Purity>98% (HPLC)
-
SolubilityDMSO : 20 mg/mL 43.04 mM; H2O : < 0.1 mg/mL
-
SMILESCC1=C(C(=O)C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C(=O)OC)C)C)C)C)O
-
Chemical Namemethyl (2S,4aS,6aR,12bR,14aR,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
BPTES
BPTES(IC50 of 0.16 μM) is an effective and specific GlutamiN/Ase GLS1 (KGA) inhibitor.
-
Benzamide, 3-methoxy...
Benzamide, 3-methoxy-N-(3-thiazolo[5,4-b]pyridin-2-ylphenyl) is a sirtuin modulator and useful for increasing the lifespan of a cell, and treating and?/or preventing a wide variety of diseases and disorders including diabetes, cardiovascular disease.
-
JGB1741
JGB1741 is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. JGB1741 modulates Bax/Bcl2 ratio, cytochrome c release and PARP cleavage and increases the acetylated p53 levels leading to p53-mediated apoptosis. JGB1741 can be used in studies about breast cancer.
